Eli Lilly and Co. /zigman2/quotes/200106384/composite LLY +0.56% said Tuesday it does not expect any shortages of medicine, including insulin, as a result of the coronavirus. The company has been monitoring its supply chain for potential impact, and does not source active pharmaceutical ingredients from China and insulin manufacturing sites in the U.S. and Europe have not been affected. "Globally, our manufacturing network is fully operational and taking steps to prevent impact," the company said in a statement. "We're also in close communication with key suppliers to ensure appropriate supplies of raw materials." Shares rose 0.5% premarket, and are up 3% in the last 12 months, while the S&P 500 /zigman2/quotes/210599714/realtime SPX +0.82% has gained 10%.
Read the full story:
Coronavirus update: 91,313 cases, 3,118 deaths, at least 105 sickened in the U.S.